Cargando…
The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls
BACKGROUND: Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk markers. In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese w...
Autores principales: | Kahal, Hassan, Aburima, Ahmed, Ungvari, Tamas, Rigby, Alan S, Coady, Anne M, Vince, Rebecca V, Ajjan, Ramzi A, Kilpatrick, Eric S, Naseem, Khalid M, Atkin, Stephen L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389314/ https://www.ncbi.nlm.nih.gov/pubmed/25880805 http://dx.doi.org/10.1186/s12902-015-0005-6 |
Ejemplares similares
-
The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome
por: Dawson, Alison J., et al.
Publicado: (2019) -
Acute Hypertriglyceridemia Induces Platelet Hyperactivity That is Not Attenuated by Insulin in Polycystic Ovary Syndrome
por: Aye, Myint Myint, et al.
Publicado: (2014) -
Pharmacological Treatment of Obesity in Patients with Polycystic Ovary Syndrome
por: Kahal, Hassan, et al.
Publicado: (2011) -
The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2017) -
The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome
por: Javed, Zeeshan, et al.
Publicado: (2020)